Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanjin Fuyan
- Development stage
- Phase 3
- Lead developer
- Guilin Sanjin Pharmaceutical
- Administration
- Oral
01
Overview
Sanjin Fuyan is a Traditional Chinese Medicine (TCM) formulation developed by Guilin Sanjin Pharmaceutical for the treatment of chronic pelvic inflammatory disease (CPID). It is specifically indicated for patients presenting with damp-heat stasis syndrome. The formulation typically functions by clearing heat, removing dampness, and promoting blood circulation to resolve stasis, thereby alleviating the inflammation and pain associated with CPID. As a botanical/herbal product, its efficacy is attributed to the synergistic effects of its constituent plant extracts, which are processed into a tablet form for oral administration.
- Brand names
- Sanjin Fuyan
- Other names
- Sanjin Fuyan TabletSanjin Fuyan Pian
02
Targets
COXIL1A (Interleukin 1 alpha)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Sanjin Fuyan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanjin Fuyan.